Skip Navigation
  Search Menu
Find an Expert


Julia Ann Beaver, M.D.

Photo of Dr. Julia Ann Beaver, M.D.

Assistant Professor of Oncology


Expertise: Breast Cancer, Cancer Genetics, Medical Oncology

Research Interests: Genetic Predisposition to Breast Cancer; Circulating Tumor DNA; Personalized Breast Cancer Therapy; Development of Novel Targeted Agents for Breast Cancer Treatment more


Sibley Memorial Hospital

5255 Loughboro Road NW
Johns Hopkins Kimmel Cancer Center
Washington, DC 20016 map
Phone: 202-660-6500
Fax: 202-660-6501


Julia A. Beaver, M.D., is a medical oncologist at Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, part of the Johns Hopkins Breast Cancer Program, and an adjunct assistant professor of oncology at Johns Hopkins University School of Medicine. Dr. Beaver is board certified in internal medicine and medical oncology by the American Board of Internal Medicine.

Dr. Beaver has an expertise in breast cancer. She sees patients with early or advanced/metastatic breast cancer for second opinion; patients with early stage breast cancer on hormonal therapy or requiring long-term follow up; and patients with ductal carcinoma in situ (DCIS).

Dr. Beaver is director of the Division of Oncology Products 1 in the Office of Hematology Oncology Products at the U.S. Food and Drug Administration (FDA). She has previously served on the Breast and Gynecologic Malignancies Group 1. Dr. Beaver is also a member of the Johns Hopkins Genomic Alterations in Tumors with Actionable Yields (GAITWAY) Molecular Profiling Tumor Board; a co-investigator for the Image Molecular Analyses Guide Efforts (IMAGE) in Breast Cancer study at Johns Hopkins; a member of the American Society of Clinical Oncology Cancer Education Committee for Drug Development and Translational Research; and a FDA liaison on Blood PAC: Blood Profiling Atlas in Cancer and the Tapestry Networks Diagnostic Quality Assurance Pilot. 

Dr. Beaver earned her medical degree from the University of Pennsylvania School of Medicine. She completed a residency in internal medicine at Johns Hopkins University School of Medicine, followed by a fellowship in medical oncology at The Johns Hopkins Sidney Kimmel Cancer Center.

Dr. Beaver is a member of the American Society of Clinical Oncology. 

Dr. Beaver has contributed to numerous publications and presentations. She was awarded the Pearl M. Stetler Research grant for her breast cancer research. Her research interests include genetic predisposition to breast cancer, circulating tumor DNA, personalized breast cancer therapy and the development of novel targeted agents for breast cancer treatment. more


  • Assistant Professor of Oncology

Departments / Divisions



  • MD, University of Pennsylvania School of Medicine - REGISTRAR (2007)


  • Johns Hopkins University School of Medicine / Internal Medicine (2010)


  • Johns Hopkins University School of Medicine / Oncology (2013)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2010)
  • American Board of Internal Medicine / Medical Oncology (2012)

Research & Publications

Selected Publications

View all on Pubmed

Beaver JA, Theoret MR, Mushti S, He K, Libeg M, Goldberg K, Sridhara R, McKee AE, Keegan P, Pazdur R. "FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma." Clin Cancer Res. 2017 Jan 10. pii: clincanres.0714.2016. doi: 10.1158/1078-0432.CCR-16-0714. [Epub ahead of print]

Singh H, Beaver JA, Kim G, Pazdur R. "Enrollment of older adults on oncology trials: An FDA perspective." J Geriatr Oncol. 2016 Dec 22. pii: S1879-4068(16)30163-1. doi: 10.1016/j.jgo.2016.11.001. [Epub ahead of print]

Beaver JA, Tzou A, Blumenthal GM, McKee AE, Kim G, Pazdur R, Philip R. "An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies." Clin Cancer Res. 2016 Dec 19. pii: clincanres.1098.2016. [Epub ahead of print]

Singh H, Brave M, Beaver JA, Cheng J, Tang S, Zahalka E, Palmby TR, Venugopal R, Song P, Liu Q, Liu C, Yu J, Chen XH, Wang X, Wang Y, Kluetz PG, Daniels SR, Papadopoulos EJ, Sridhara R, McKee AE, Ibrahim A, Kim G, Pazdur R. "U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma." Clin Cancer Res. 2017 Jan 15;23(2):330-335. doi: 10.1158/1078-0432.CCR-16-1073.

Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH. "Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer." Clin Cancer Res. 2017 Jan 15;23(2):379-386. doi: 10.1158/1078-0432.CCR-16-1543.

Activities & Honors


  • Pearl M. Stetler Research Grant, Johns Hopkins Medicine


  • American Society of Clinical Oncology


Videos & Media

Recent News Articles and Media Coverage

Improving Cancer Clinical Trial Participation and Eligibility Criteria. Cancer Network. (06/01/2017)

Revising Entry Criteria Key to Maximizing Clinical Trial Participation. ASCO Daily News. (06/01/2017)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile